Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU
Press release, Helsinki, 17May2023 at 2 PM (EEST)
Nexstim’s QualitySystem and NBS 6 Receive MDR Certification in the EU
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received certifications for its quality management system and NBS 6 product under MDR (Regulation (EU) 2017/745) in the European Union.
The EU quality management system certificate allows for Nexstim to start marketing and selling the NBS 6 system for the treatment of major depression and chronic neuropathic pain within the European Union. Nexstim announced on April 17, 2023, that it had launched NBS 6 in the United States for the treatment of Major Depressive Disorder (MDD).
The NBS 6 enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or treatment interests.
Mikko Karvinen, CEO of Nexstim, comments:
“The MDR conformity certification is an important step in the process of launching theNBS 6 and achieving one of our keystrategic objectives for 2023. I am proud of the hard work our team has put into making the new software generation available in both the United States and the European Union in such a tight schedule. The EU quality management system certification will benefit us in the long term also by making any future product certification processes more efficient.
The NBS 6 received a great response as we attended and unveiled the product at the Clinical TMS Society Annual Meeting in Colorado Springs, United States earlier this month. We are expecting nothing less from the European market and are excited to continue the promotion work.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Første uge i tilbudsperioden i Jobindex A/S10.6.2023 12:00:37 CEST | pressemeddelelse
Danielsen 2 aps - der er hovedaktionær i Jobindex A/S - har den 2. juni 2023 fremsat et frivilligt ureguleret offentligt købstilbud om at købe aktier i Jobindex A/S til en pris på 1900 kr. pr. aktie i forbindelse med ansøgning om afnotering fra First North. På tilbudsperiodens tredje og fjerde dag har Danielsen 2 aps købt 1212 og 944 aktier á 1900 kr. pr. aktie. Den første uge har Danielsen 2 aps i alt købt 4645 aktier. Tilbudsperioden fortsætter indtil den 30. juni 2023. Det forventes at Jobindex A/S derefter vil blive afnoteret og slettet fra handel på Nasdaq First North i henhold til punkt 2.6(c)(i) i Supplement D i Nasdaqs regler. Yderligere oplysninger Direktør Kaare Danielsen, telefon 20735010, email email@example.com Certified Adviser Jakob Tolstrup Kristensen, email firstname.lastname@example.org Vedhæftet fil Aktiehandel tilbud 2023 juni 9
PRIX FITZGERALD 2023 LAUREATE ANNOUNCED AT HÔTEL BELLES RIVES10.6.2023 01:03:24 CEST | Press release
Quentin Tarantino Accepts 12th Annual Literary Award for Cinema Speculation CAP D’ANTIBES, France, June 09, 2023 (GLOBE NEWSWIRE) -- During an unforgettable ceremony held this evening Hôtel Belles Rives in Juan-les-Pins on the French Riviera, jury members of the 2023 Prix Fitzgerald, a French literary award created in 2011 by Marianne Estène-Chauvin, President of the Francis Scott Fitzgerald Academy and owner of Belles Rives Group, announced today this year’s laureate. The long-awaited first work of nonfiction from the author of the #1 New York Times bestselling Once Upon a Time in Hollywood, Quentin Tarantino accepted the prize for Cinema Speculation, published by HarperCollins in the United States and Weidenfeld & Nicolson in the United Kingdom on November 1, 2022 and French publishing house, Flammarion on March 22, 2023. Every year in June, the Hôtel Belles Rives hosts the Prix Fitzgerald, which honors a novel or short story that reflects the elegance, spirit, and art of living embo
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease10.6.2023 00:45:00 CEST | Press release
Peripheral and Central Nervous System Drugs Advisory Committee votedbased on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer’s disease on January 6, 2023 TOKYO and CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous
Travel Startup Yovivo Expands Core Team With New Staff Members9.6.2023 20:47:00 CEST | Press release
Extended stays booking site hires Karen Kochmann (Ex-Expedia) and Erik Beekman (Ex Savills) to keep up with its fast expansion ROTTERDAM, Netherlands, June 09, 2023 (GLOBE NEWSWIRE) -- Growing startup Yovivo.com today announced its latest team expansion with the addition of two key members from the travel and real estate industries. Karen Kochmann has been taken on by Yovivo in the position of Strategic Growth Manager. Formerly Expedia’s Account Manager for the Balearic Islands (where the Yovivo offices and team are located), Karen boasts over seven years of experience, a masters degree in Digital Marketing and E-commerce, and a Banking degree from Lauder Business School. “I plan to developing strategic partnerships which will help Yovivo grow and position itself as a leading brand for extended stays. With my experience in the field of tech and tourism I will be able to bring fresh ideas to both the development of the platform and the B2C and B2B approach planned. I'll also focus on cr
Nokia Corporation: Repurchase of own shares on 09.06.20239.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 9 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 09.06.2023 Espoo, Finland – On 9 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL323,9103.77CEUX33,5313.77AQEU1,0683.77TQEX14,9913.77Total373,5003.77 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and e